Centennial, CO – According to filings with the U.S. Securities and Exchange Commission, Cell Point is raising $33,425,675.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Greg Colip played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cell Point
Cell>Point is a late stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases. The company was established in 2001 to develop and commercialize molecular imaging and targeted therapeutics based on 5 platform technologies licensed from The University of Texas MD Cancer Center. Cell>Point’s lead product in clinical development is ethylenedicysteine-glucosamine which the company registered under the trademark Oncardia. With applications in cancer and cardiovascular disease, Oncardia can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic products. Oncardia’s mechanism allows it to target the diseased cell and then deliver its radionuclide or cold metal into the cell nucleus. Cell>Point refers to this as intra-nuclear therapy.

To learn more about Cell Point, visit http://cellpointweb.com/

Contact:
Greg Colip, Chief Executive Officer
303-689-9693
greg.colip@cellpointweb.com
https://www.linkedin.com/in/greg-colip-05765b20/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved